No Detail Found!

Evaluation of the hepatic effect of concomitant administration of ciprofloxacin and some antimalarial drugs in Plasmodium berghei infected mice: an in vivo study.

Author(s)
Kosisochi Chinwendu Amorha Clinical Pharmacokinetic Research Unit, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu State, Nigeria
Onyinyechukwu Blessing Ugwuowo Clinical Pharmacokinetic Research Unit, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu State, Nigeria
Ebere Emilia Ayogu Clinical Pharmacokinetic Research Unit, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu State, Nigeria
Sunday Odunke Nduka Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria
Mathew Jegbefume Okonta Clinical Pharmacokinetic Research Unit, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu State, Nigeria
Abstract
This study evaluated the hepatotoxic effects of artesunate (AS), artemether-lumefantrine (AL) and artesunateamodiaquine (ASAQ) co-administration with ciprofloxacin (CIP) using animal model. Chloroquine sensitive Plasmodium berghei NK65 strain infected albino mice (120) were utilized for this study, carried out in three phases. Phase 1 comprised eleven groups treated with different doses of either AS, AL, ASAQ or CIP alone. Phase 2 consisted of nine groups treated with 7mg/kg of CIP combined with different doses of AS, AL, ASAQ. Phase 3 comprised ten groups treated with 14mg/kg of CIP (CIP2) with different doses of AS, AL, ASAQ. Seventy-two hours after administration of drugs, toxicity was determined by evaluating the effect of drugs on liver enzymes using spectrophotometer. Statistical analysis revealed that CIP alone significantly (P<0.05) reduced the levels of Aspartate Transaminase (AST) and Serum Alanine Transaminase (ALT) compared to AS, AL and ASAQ alone. Combination of different doses of AS, AL and ASAQ with 7mg/kg CIP significantly increased the level of AST and ALT while combination of AS, AL and ASAQ with 14mg/kg CIP significantly decreased AST and ALT levels. Care should be taken during the co-administration of low dose ciprofloxacin with artesunate, artemether-lumefantrine or artesunate-amodiaquine.
Publication Details
Page(s) 1805-1811
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 31, Issue: 5, Year: 2018

Request the full text from PASTIC

Keywords
Artemisinin combination therapy
0

Citations

0

Downloads

67

Views